Metabolic effects of second-generation antipsychotics in bipolar youth: Comparison with other psychotic and nonpsychotic diagnoses

Bipolar Disorders

Volumn 12, Issue 2, 2010, Pages 172-184

  Moreno, Carmen ^a   Merchán Naranjo, Jessica ^a   Álvarez, Mar ^a   Baeza, Inmaculada ^b   Alda, Jose A ^c   Martínez Cantarero, Carmen ^d   Parellada, Mara ^a   Sánchez, Bernardo ^c   de la Serna, Elena ^b   Giraldez, Marisa ^a   Arango, Celso ^a  

^a CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c HOSPITAL SANT JOAN DE DÉU   (Spain)

^d HOSPITAL INFANTIL UNIVERSITARIO NIÑO JESÚS   (Spain)

Author keywords

Adolescents; Bipolar disorder; Body mass index; Children; Metabolism; Psychotic disorder; Second generation antipsychotics; Weight gain

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; BENZODIAZEPINE DERIVATIVE; BIOLOGICAL MARKER; DIBENZOTHIAZEPINE DERIVATIVE; THYROXINE;

ADOLESCENT; ARTICLE; BIPOLAR DISORDER; BODY MASS; CHILD; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; METABOLIC PARAMETERS; NATURALISTIC INQUIRY; OBESITY; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOSIS; RISK ASSESSMENT; SCHOOL CHILD; SIDE EFFECT; STATISTICAL SIGNIFICANCE; WEIGHT GAIN; BLOOD; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG EFFECTS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MENTAL DISORDERS; MULTICENTER STUDY; PSYCHOTIC DISORDERS; TREATMENT OUTCOME;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BIOLOGICAL MARKERS; BIPOLAR DISORDER; BODY MASS INDEX; CHILD; CHOLESTEROL, LDL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIBENZOTHIAZEPINES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MENTAL DISORDERS; OBESITY; PSYCHOTIC DISORDERS; RISPERIDONE; THYROXINE; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 77955152516     PISSN: 13985647     EISSN: 13995618     Source Type: Journal    
DOI: 10.1111/j.1399-5618.2010.00797.x     Document Type: Article

References (57)

1. Newcomer JW. Medical risk in patients with bipolar disorder and schizophrenia. J Clin Psychiatry 2006, 67:25-30.
2. Colton CW, Manderscheid RW. Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. Prev Chronic Dis 2006, 3:A42.
3. Bobes J, Arango C, Aranda P, Carmena R, Garcia-Garcia M, Rejas J. Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: results of the CLAMORS Study. Schizophr Res 2007, 90:162-173.
4. Taylor V, MacQueen G. Associations between bipolar disorder and metabolic syndrome: a review. J Clin Psychiatry 2006, 67:1034-1041.
5. Fagiolini A, Chengappa KN, Soreca I, Chang J. Bipolar disorder and the metabolic syndrome: causal factors, psychiatric outcomes and economic burden. CNS Drugs 2008, 22:655-669.
6. Correll CU, Frederickson AM, Kane JM, Manu P. Equally increased risk for metabolic syndrome in patients with bipolar disorder and schizophrenia treated with second-generation antipsychotics. Bipolar Disord 2008, 10:788-797.
7. Birkenaes AB, Opjordsmoen S, Brunborg C. The level of cardiovascular risk factors in bipolar disorder equals that of schizophrenia: a comparative study. J Clin Psychiatry 2007, 68:917-923.
8. Regenold WT, Thapar RK, Marano C, Gavirneni S, Kondapavuluru PV. Increased prevalence of type 2 diabetes mellitus among psychiatric inpatients with bipolar I affective and schizoaffective disorders independent of psychotropic drug use. J Affect Disord 2002, 70:19-26.
9. Garcia-Portilla MP, Saiz PA, Bascaran MT. Cardiovascular risk in patients with bipolar disorder. J Affect Disord 2009, 115:302-308.
10. Bobes J, Sáiz-Ruiz J, Montes JM, Mostaza J, Rico-Villademoros F, Vieta E. Consenso Español de Salud Física del Paciente con Trastorno Bipolar. Rev Psiquiatr Salud Ment (Barc) 2008, 1:26-37.
11. Correll CU, Carlson HE. Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. J Am Acad Child Adolesc Psychiatry 2006, 45:771-791.
12. Olfson M, Blanco C, Liu L, Moreno C, Laje G. National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. Arch Gen Psychiatry 2006, 63:679-685.
13. Tohen M, Kryzhanovskaya L, Carlson G. Olanzapine versus placebo in the treatment of adolescents with bipolar mania. Am J Psychiatry 2007, 164:1547-1556.
14. Haas M, DelBello MP, Pandina G. Risperidone for the treatment of acute mania in children and adolescents with bipolar disorder: a randomized, double-blind, placebo-controlled study. Bipolar Disord 2009, 11:687-700.
15. The Management of Bipolar Disorder in Adults, Children and Adolescents, in Primary and Secondary Care http://www.nice.org.uk/Guidance/CG38, Available from: Accessed January 15, 2010
16. Kowatch RA, Fristad M, Birmaher B, Wagner KD, Findling RL, Hellander M. Treatment guidelines for children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry 2005, 44:213-235.
17. Woods SW, Martin A, Spector SG, McGlashan TH. Effects of development on olanzapine-associated adverse events. J Am Acad Child Adolesc Psychiatry 2002, 41:1439-1446.
18. Correll CU, Mughal T, Parikh U, Kane JM, Malhotra AK. Atypical antipsychotic-induced changes in body composition, lipid metabolism, and insulin resistance in antipsychotic-naive youth. Schizophr Bull 2007, 33:496-497.
19. Correll CU. Assessing and maximizing the safety and tolerability of antipsychotics used in the treatment of children and adolescents. J Clin Psychiatry 2008, 69:26-36.
20. Correll CU, Penzner JB, Parikh UH. Recognizing and monitoring adverse events of second-generation antipsychotics in children and adolescents. Child Adolesc Psychiatr Clin N Am 2006, 15:177-206.
21. Berenson GS. Obesity-a critical issue in preventive cardiology: the Bogalusa Heart Study. Prev Cardiol 2005, 8:234-241.
22. van Winkel R, van Os J, Celic I. Psychiatric diagnosis as an independent risk factor for metabolic disturbances: results from a comprehensive, naturalistic screening program. J Clin Psychiatry 2008, 69:1319-1327.
23. Kilbourne AM, Brar JS, Drayer RA, Xu X, Post EP. Cardiovascular disease and metabolic risk factors in male patients with schizophrenia, schizoaffective disorder, and bipolar disorder. Psychosomatics 2007, 48:412-417.
24. Laita P, Cifuentes A, Doll A. Antipsychotic-related abnormal involuntary movements and metabolic and endocrine side effects in children and adolescents. J Child Adolesc Psychopharmacol 2007, 17:487-502.
25. Fraguas D, Merchan-Naranjo J, Laita P. Metabolic and hormonal side effects in children and adolescents treated with second-generation antipsychotics. J Clin Psychiatry 2008, 69:1166-1175.
26. Sobradillo B, Aguirre A, Aresti U. Curvas y tablas de crecimiento (estudios longitudinal y transversal) 2004, 1-36. Bilbao, Fundacion Faustino Orbegozo Eizaguirre
27. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 2004, 114:555-576.
28. Serra Majem L, Ribas Barba L, Aranceta Bartrina J, Perez Rodrigo C, Saavedra Santana P, Pena Quintana L. Childhood and adolescent obesity in Spain. Results of the enKid study (1998-2000). Med Clin (Barc) 2003, 121:725-732.
29. Fagiolini A, Frank E, Houck PR. Prevalence of obesity and weight change during treatment in patients with bipolar I disorder. J Clin Psychiatry 2002, 63:528-533.
30. Egger J, Brett EM. Effects of sodium valproate in 100 children with special reference to weight. Br Med J (Clin Res Ed) 1981, 283:577-581.
31. DelBello MP, Kowatch RA, Adler CM. A double-blind randomized pilot study comparing quetiapine and divalproex for adolescent mania. J Am Acad Child Adolesc Psychiatry 2006, 45:305-313.
32. Biederman J, Mick E, Hammerness P. Open-label, 8-week trial of olanzapine and risperidone for the treatment of bipolar disorder in preschool-age children. Biol Psychiatry 2005, 58:589-594.
33. Biederman J, Mick E, Wozniak J, Aleardi M, Spencer T, Faraone SV. An open-label trial of risperidone in children and adolescents with bipolar disorder. J Child Adolesc Psychopharmacol 2005, 15:311-317.
34. MacMillan CM, Withney JE, Korndorfer SR, Tilley CA, Mrakotsky C, Gonzalez-Heydrich JM. Comparative clinical responses to risperidone and divalproex in patients with pediatric bipolar disorder. J Psychiatr Pract 2008, 14:160-169.
35. Shaw JA, Lewis JE, Pascal S. A study of quetiapine: efficacy and tolerability in psychotic adolescents. J Child Adolesc Psychopharmacol 2001, 11:415-424.
36. Sikich L, Hamer RM, Bashford RA, Sheitman BB, Lieberman JA. A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial. Neuropsychopharmacology 2004, 29:133-145.
37. Schimmelmann BG, Mehler-Wex C, Lambert M. A prospective 12-week study of quetiapine in adolescents with schizophrenia spectrum disorders. J Child Adolesc Psychopharmacol 2007, 17:768-778.
38. Dittmann RW, Meyer E, Freisleder FJ. Effectiveness and tolerability of olanzapine in the treatment of adolescents with schizophrenia and related psychotic disorders: results from a large, prospective, open-label study. J Child Adolesc Psychopharmacol 2008, 18:54-69.
39. Findling RL. Atypical antipsychotic treatment of disruptive behavior disorders in children and adolescents. J Clin Psychiatry 2008, 69:9-14.
40. McDougle CJ, Stigler KA, Erickson CA, Posey DJ. Atypical antipsychotics in children and adolescents with autistic and other pervasive developmental disorders. J Clin Psychiatry 2008, 69:15-20.
41. Goldstein BI, Birmaher B, Axelson DA. Preliminary findings regarding overweight and obesity in pediatric bipolar disorder. J Clin Psychiatry 2008, 69:1953-1959.
42. Kim B, Kim SJ, Son JI, Joo YH. Weight change in the acute treatment of bipolar I disorder: a naturalistic observational study of psychiatric inpatients. J Affect Disord 2008, 105:45-52.
43. Olfson M, Marcus SC, Corey-Lisle P, Tuomari AV, Hines P, L'Italien GJ. Hyperlipidemia following treatment with antipsychotic medications. Am J Psychiatry 2006, 163:1821-1825.
44. Kumra S, Kranzler H, Gerbino-Rosen G. Clozapine and " high-dose" olanzapine in refractory early-onset schizophrenia: a 12-week randomized and double-blind comparison. Biol Psychiatry 2008, 63:524-529.
45. Reyes M, Buitelaar J, Toren P, Augustyns I, Eerdekens M. A randomized, double-blind, placebo-controlled study of risperidone maintenance treatment in children and adolescents with disruptive behavior disorders. Am J Psychiatry 2006, 163:402-410.
46. Aman MG, De Smedt G, Derivan A, Lyons B, Findling RL. Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. Am J Psychiatry 2002, 159:1337-1346.
47. McCracken JT, McGough J, Shah B. Risperidone in children with autism and serious behavioral problems. N Engl J Med 2002, 347:314-321.
48. Findling RL, McNamara NK, Gracious BL. Quetiapine in nine youths with autistic disorder. J Child Adolesc Psychopharmacol 2004, 14:287-294.
49. Birkenaes AB, Birkeland KI, Engh JA. Dyslipidemia independent of body mass in antipsychotic-treated patients under real-life conditions. J Clin Psychopharmacol 2008, 28:132-137.
50. Bergman RN, Ader M. Atypical antipsychotics and glucose homeostasis. J Clin Psychiatry 2005, 66:504-514.
51. Arango C, Robles O, Parellada M. Olanzapine compared to quetiapine in adolescents with a first psychotic episode. Eur Child Adolesc Psychiatry 2009, 18:418-428.
52. Kelly DL, Conley RR. Thyroid function in treatment-resistant schizophrenia patients treated with quetiapine, risperidone, or fluphenazine. J Clin Psychiatry 2005, 66:80-84.
53. Jublanc C, Bruckert E, Giral P. Relationship of circulating C-reactive protein levels to thyroid status and cardiovascular risk in hyperlipidemic euthyroid subjects: low free thyroxine is associated with elevated hsCRP. Atherosclerosis 2004, 172:7-11.
54. Correll CU. Weight gain and metabolic effects of mood stabilizers and antipsychotics in pediatric bipolar disorder: a systematic review and pooled analysis of short-term trials. J Am Acad Child Adolesc Psychiatry 2007, 46:687-700.
55. Birmaher B, Axelson D, Goldstein B. Four-year longitudinal course of children and adolescents with bipolar spectrum disorders: the Course and Outcome of Bipolar Youth (COBY) study. Am J Psychiatry 2009, 166:795-804.
56. Bhangoo RK, Lowe CH, Myers FS. Medication use in children and adolescents treated in the community for bipolar disorder. J Child Adolesc Psychopharmacol 2003, 13:515-522.
57. Castro-Fornieles J, Parellada M, Gonzalez-Pinto A. The Child and Adolescent First-Episode Psychosis Study (CAFEPS): design and baseline results. Schizophr Res 2007, 91:226-237.